Spontaneous Dissection of Left Internal Mammary Artery Graft: A Case Report and Literature Review.

Autor: Riku S; Department of Cardiology, Handa City Hospital, Handa, Japan; Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan; Department of Cardiology, Nakatsugawa Municipal General Hospital, Nakatsugawa, Japan., Suzuki S; Department of Cardiology, Handa City Hospital, Handa, Japan; Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan., Tanaka A; Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan. Electronic address: akihito17491194@gmail.com., Murohara T; Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Jazyk: angličtina
Zdroj: Cardiovascular revascularization medicine : including molecular interventions [Cardiovasc Revasc Med] 2023 Aug; Vol. 53S, pp. S235-S238. Date of Electronic Publication: 2022 Apr 30.
DOI: 10.1016/j.carrev.2022.04.007
Abstrakt: Spontaneous left internal mammary artery (LIMA) graft dissection is a rare condition, and clinical findings remain to be elucidated. We report a case of LIMA graft dissection diagnosed by a coronary computed tomography and intravascular ultrasound. The patient was successfully treated with percutaneous intervention. We also conducted a literature review of published cases and summarized the clinical presentation, pathophysiology, diagnosis, and treatment.
Competing Interests: Declaration of competing interest Toyoaki Murohara received lecture fees from Bayer Pharmaceutical Co., Ltd., Daiichi-Sankyo Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Kowa Co., Ltd., MSD K. K., Mitsubishi Tanabe Pharma Co., Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K. K., Pfizer Japan Inc., Sanofi-aventis K. K., and Takeda Pharmaceutical Co., Ltd. Toyoaki Murohara received unrestricted research grant for Department of Cardiology, Nagoya University Graduate School of Medicine from Astellas Pharma Inc., Daiichi-Sankyo Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Kowa Co., Ltd., MSD K. K., Mitsubishi Tanabe Pharma Co., Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K. K., Otsuka Pharma Ltd., Pfizer Japan Inc., Sanofi-aventis K. K., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
(Copyright © 2022 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: